Published in Acta Neurol Scand on October 01, 1985
The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol (1989) 1.25
Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. Br J Clin Pharmacol (2002) 0.89
Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J Neural Transm (Vienna) (2013) 0.84
Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease. Mov Disord (2012) 0.77
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease. Behav Brain Res (2016) 0.75
A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. BMC Complement Altern Med (2014) 0.75
Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev (1999) 3.81
POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement. Neurology (2004) 1.89
Diagnosis and clinical characteristics of ocular Lyme borreliosis. Am J Ophthalmol (1995) 1.65
A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry (1998) 1.60
Comparative liver toxicity of various erythromycin derivatives in animals. J Antimicrob Chemother (1988) 1.41
On the role of prolyl oligopeptidase in health and disease. Neuropeptides (2006) 1.39
Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol (1995) 1.33
Impairing effect of food on ketoconazole absorption. Antimicrob Agents Chemother (1982) 1.32
Laminin is induced in astrocytes of adult brain by injury. EMBO J (1984) 1.28
Executive functions and speed of mental processing in elderly patients with frontal or nonfrontal ischemic stroke. Eur J Neurol (1999) 1.27
White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. Eur Neurol (1998) 1.25
Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob Agents Chemother (1983) 1.24
White matter hyperintensities as a predictor of neuropsychological deficits post-stroke. J Neurol Neurosurg Psychiatry (2005) 1.24
Hypoxanthine-guanine phosphoribosyltransferase variants: correlation of clinical phenotype with enzyme activity. J Inherit Metab Dis (1981) 1.23
Poststroke depression and lesion location revisited. J Neuropsychiatry Clin Neurosci (2004) 1.21
Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem (1994) 1.17
Cognitive profile of subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry (2006) 1.16
Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol (1995) 1.12
Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. J Med Chem (1989) 1.12
Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord (2003) 1.11
Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J (1996) 1.10
High-level production of human type I collagen in the yeast Pichia pastoris. Yeast (2001) 1.10
Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur J Pharmacol (1988) 1.09
How complex interactions of ischemic brain infarcts, white matter lesions, and atrophy relate to poststroke dementia. Arch Neurol (2000) 1.09
Mutacin production by Streptococcus mutans may promote transmission of bacteria from mother to child. Infect Immun (1998) 1.08
Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol (1990) 1.04
Utilization of purines by an HPRT variant in an intelligent, nonmutilative patient with features of the Lesch-Nyhan syndrome. Pediatr Res (1979) 1.03
Clinical and genetic findings in Finnish ataxia patients with the spinocerebellar ataxia 8 repeat expansion. Ann Neurol (2000) 1.03
Effect of food on the bioavailability of labetalol. Br J Clin Pharmacol (1980) 1.00
Magnetic resonance imaging correlates of depression after ischemic stroke. Arch Gen Psychiatry (2001) 0.99
The pharmacokinetics of dihydroergotamine in the beagle. Int J Clin Pharmacol Biopharm (1978) 0.97
Effect of lithium and rubidium on the sleeping time caused by various intravenous anaesthetics in the mouse. Br J Anaesth (1976) 0.97
MRI correlates of executive dysfunction in patients with ischaemic stroke. Eur J Neurol (2003) 0.97
Pharmacokinetics of nalidixinic acid and oxolinic acid in healthy women. Clin Pharmacol Ther (1976) 0.97
Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav Brain Res (1997) 0.97
Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res (1992) 0.96
New selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol Sci (1989) 0.96
Improved assay of reaction products to quantitate catechol-O-methyltransferase activity by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl (1995) 0.96
Effects of haloperidol on selective attention: a combined whole-head MEG and high-resolution EEG study. Neuropsychopharmacology (2001) 0.96
Intramuscular absorption of dihydroergotamine in man. Int J Clin Pharmacol Biopharm (1978) 0.95
7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety. Psychopharmacology (Berl) (1997) 0.95
Dihydroergotamine: pharmacokinetics and usefulness in spinal anaesthesia. Acta Anaesthesiol Scand (1978) 0.94
The energy charge in wild-type and respiration-deficient Chinese hamster cell mutants. J Cell Physiol (1980) 0.93
Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. Vaccine (1999) 0.92
A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. Br J Pharmacol (2012) 0.92
Catecholamine metabolism in the brain by membrane-bound and soluble catechol-o-methyltransferase (COMT) estimated by enzyme kinetic values. Med Hypotheses (2001) 0.91
Activation of 5-HT2A receptors impairs response control of rats in a five-choice serial reaction time task. Neuropharmacology (2000) 0.91
Expression of recombinant human type I-III collagens in the yeast pichia pastoris. Biochem Soc Trans (2000) 0.91
Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner. Br J Pharmacol (2011) 0.91
Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone. Clin Pharmacol Ther (1990) 0.91
Absorption of erythromycin acistrate and erythromycin base in the fasting and non-fasting state. J Antimicrob Chemother (1988) 0.91
General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol (1994) 0.91
Suppression of transient 40-Hz auditory response by haloperidol suggests modulation of human selective attention by dopamine D2 receptors. Neurosci Lett (2000) 0.91
Effect of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and coagulation. J Clin Pharmacol (1984) 0.90
Effect of age on the pharmacokinetics of diazepam given in conjunction with spinal anesthesia. Anesthesiology (1979) 0.90
How useful is [123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry (2005) 0.89
MRI correlates of dementia after first clinical ischemic stroke. J Neurol Sci (2000) 0.88
Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci (1988) 0.88
Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats. Eur J Neurosci (2000) 0.88
Hippocampal and temporal lobe atrophy and age-related decline in memory. Acta Neurol Scand (2000) 0.88
Impairment of captopril bioavailability by concomitant food and antacid intake. Int J Clin Pharmacol Ther Toxicol (1984) 0.88
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol (1995) 0.88
Striatal membrane-bound and soluble catechol-O-methyl-transferase after selective neuronal lesions in the rat. J Neural Transm (1987) 0.88
Bioavailability of four different pharmaceutical preparations of carbamazepine. Acta Pharmacol Toxicol (Copenh) (1978) 0.88
Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. Eur J Pharmacol (1999) 0.87
Catechol-O-methyltransferase activity in human and rat small intestine. Life Sci (1988) 0.87
Expression and traffic of cellular prolyl oligopeptidase are regulated during cerebellar granule cell differentiation, maturation, and aging. Neuroscience (2008) 0.87
Effects of two erythromycins, doxycycline and phenoxymethylpenicillin on human leucocyte chemotaxis in vitro. J Antimicrob Chemother (1988) 0.86
Computerized rotometer apparatus for recording circling behavior. Methods Find Exp Clin Pharmacol (1989) 0.86
Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos (1993) 0.86
Clinical and radiological determinants of prestroke cognitive decline in a stroke cohort. J Neurol Neurosurg Psychiatry (1999) 0.85
Purification and heterogeneity of human kininogen. Use of DEAE-chromatography, molecular sieving and antibody specific immunosorbents. Int J Pept Protein Res (1975) 0.85
Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol (1990) 0.85
Fate of single oral doses of erythromycin acistrate, erythromycin stearate and pelleted erythromycin base analysed by mass-spectrometry in plasma of healthy human volunteers. J Antimicrob Chemother (1988) 0.85
Clinical advantages of COMT inhibition with entacapone - a review. J Neural Transm (Vienna) (2004) 0.85
Medial temporal lobe atrophy and memory deficits in elderly stroke patients. Eur J Neurol (2004) 0.85
Cholecystokinin2 receptor-deficient mice display altered function of brain dopaminergic system. Psychopharmacology (Berl) (2001) 0.85
Effects of systemic carbidopa on dopamine synthesis in rat hypothalamus and striatum. J Neural Transm Park Dis Dement Sect (1992) 0.84
Fibrinogen gene promoter -455 A allele as a risk factor for lacunar stroke. Stroke (2003) 0.84
Tonsillar penetration of erythromycin and its 2'-acetyl ester in patients with chronic tonsillitis. J Antimicrob Chemother (1988) 0.84
Auditory sensory memory and the cholinergic system: implications for Alzheimer's disease. Neuroimage (2001) 0.84
Effects of methylmercaptoimidazole (MMI), propylthiouracil (PTU), potassium perchlorate (KClO4) and potassium iodide (KI) on the serum concentrations of thyrotrophin (TSH) and thyroid hormones in the rat. Acta Endocrinol (Copenh) (1979) 0.84
Tumor-producing and skin-irritating activity of dithranol (anthralin) and its 10-acyl analogues in SENCAR mice. Carcinogenesis (1986) 0.84
Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A. Clin Exp Immunol (2011) 0.84
Effects of levo- and dextrosimendan on NF-kappaB-mediated transcription, iNOS expression and NO production in response to inflammatory stimuli. Br J Pharmacol (2008) 0.84
Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo. Neuroscience (2011) 0.83